Anbogen Therapeutics, Inc.
TTPEX:778410.15
TWD
+0.29
(+2.94%)
Anbogen Therapeutics, Inc.
TPEX:7784
(Taipei Exchange)
Recent
price
10.15
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Anbogen Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops targeted small-molecule therapeutics and peptide-based drug conjugates for precision oncology. The company focuses on translating preclinical scientific innovations into targeted cancer therapies designed to overcome therapeutic resistance and address unmet medical needs. Its research and development pipeline comprises ABT-101, an oral, irreversible tyrosine kinase inhibitor targeting EGFR and HER2 exon 20 insertion mutations for the treatment of non-small cell lung cancer; ABT-301 (Imofinostat), a selective Class I histone deacetylase inhibitor designed to remodel the immunosuppressive tumor microenvironment, undergoing clinical evaluation in combination with immune checkpoint inhibitors and anti-angiogenic agents for metastatic colorectal cancer, pancreatic cancer, and other solid tumors; ABT-202, a second-generation pan-KRAS inhibitor engineered to target oncogenic mutations and overcome resistance mechanisms in KRAS-driven malignancies; and ABT-501, a targeted peptide-drug conjugate directed against luteinizing hormone-releasing hormone receptor-positive neoplasms, including triple-negative breast cancer and ovarian cancer. The company conducts clinical and preclinical development activities across Taiwan, the United States, and the broader Asia-Pacific region. Founded in 2019, Anbogen Therapeutics, Inc. is headquartered in Taipei, Taiwan, and is listed on the Emerging Stock Board of the Taipei Exchange under ticker symbol 7784. In recent developments, the company registered and commenced trading on the Taipei Exchange Emerging Stock Board in May 2026, entered into an international collaborative research agreement with The University of Tokyo in August 2026 to evaluate ABT-301 across multiple solid tumor indications through translational veterinary oncology models, and advanced its strategic capitalization initiatives with a 150 million dollar funding framework to support global multi-center clinical trials.